All the effects observed in the present study are attributable solely to Aurora kinase A or PLK1 inhibition, suggesting that danusertib or volasertib could be an alternative strategy to treat relapsed/resistant CML patients. The gene discussed is PLK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.